DS
FNCH

David Shaw’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

David Shaw’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-639
Closed -$96K – 5955
2022
Q1 		$96K Sell
639
-276
-30% -$63.7K ﹤0.01% 5005
2021
Q4 		$274K Buy
+915
New +$351K ﹤0.01% 4726

Other funds holding FNCH

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
AMC
Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
TA
TRB Advisors New York $233M AUM 14.81% 1-Year Est. Return
MP
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.88B AUM 54.21% 1-Year Est. Return

David Shaw's FNCH Position: Q2 2022 in Review

David Shaw sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2022, closing a stake of 639 shares — an estimated $96K sold.

David Shaw first reported a position in FNCH in Q4 2021 and held it in 2 quarters. The position peaked at $274K in Q4 2021. 46 funds tracked by Wall St. Rank hold FNCH as of Q2 2022.

  • David Shaw reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • David Shaw sold 639 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2022, an estimated $96K.
  • David Shaw first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • David Shaw's Finch Therapeutics Group, Inc. Common Stock position peaked at $274K in Q4 2021.
  • 46 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.